{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:38:23Z","timestamp":1787027903823,"version":"build-2736575974"},"reference-count":34,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Dose-dense chemotherapy shortens the interval between chemotherapy cycles and has shown improved outcomes in high-risk breast cancer patients. We retrospectively evaluated the efficacy and safety of dose-dense chemotherapy in 80 breast cancer patients treated at our hospital from 2020 to 2024. The regimen included epirubicin and cyclophosphamide followed by paclitaxel or docetaxel, with pegfilgrastim support. The overall treatment completion rate was 82.5%. Of the 80 patients, 55 underwent neoadjuvant chemotherapy, and the pathological complete response rate was significantly higher in triple-negative breast cancer (59.1%) compared to that in luminal-type cancer (9.1%). Common adverse events included anemia, liver dysfunction, myalgia, and peripheral neuropathy. Febrile neutropenia occurred in 8.8% of patients, with some cases linked to pegfilgrastim body pod use, particularly in individuals with low subcutaneous fat. Notably, two patients developed pneumocystis pneumonia, potentially associated with steroid administration. Despite these toxicities, most were manageable and resolved after treatment. Our findings support the efficacy of dose-dense chemotherapy, particularly in triple-negative breast cancer, while highlighting the importance of individualized supportive care and vigilance regarding hematologic and infectious complications.<\/jats:p>","DOI":"10.3390\/curroncol32080441","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:25:11Z","timestamp":1754486711000},"page":"441","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and Safety of Dose-Dense Chemotherapy in Breast Cancer: Real Clinical Data and Literature Review"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2708-4550","authenticated-orcid":false,"given":"Keiko","family":"Yanagihara","sequence":"first","affiliation":[{"name":"Department of Breast Surgery and Oncology, Nippon Medical School Tama-Nagayama Hospital, 1-7-1 Nagayama, Tama-shi, Tokyo 206-8512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Nippon Medical School Tama-Nagayama Hospital, 1-7-1 Nagayama, Tama-shi, Tokyo 206-8512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamami","family":"Yamakawa","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology, Nippon Medical School Tama-Nagayama Hospital, 1-7-1 Nagayama, Tama-shi, Tokyo 206-8512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sena","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology, Nippon Medical School Tama-Nagayama Hospital, 1-7-1 Nagayama, Tama-shi, Tokyo 206-8512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Tamura","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery and Oncology, Nippon Medical School Tama-Nagayama Hospital, 1-7-1 Nagayama, Tama-shi, Tokyo 206-8512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Nagata","sequence":"additional","affiliation":[{"name":"Department of Pathology, Nippon Medical School Tama-Nagayama Hospital, 1-7-1 Nagayama, Tama-shi, Tokyo 206-8512, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13058-024-01881-y","article-title":"Metastatic recurrence in women diagnosed with non-metastatic breast cancer: A systematic review and meta-analysis","volume":"26","author":"Morgan","year":"2024","journal-title":"Breast Cancer Res."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"112712","DOI":"10.18632\/oncotarget.22521","article-title":"The survival benefit of neoadjuvant chemotherapy and pCR among patients with advanced stage triple negative breast cancer","volume":"8","author":"Biswas","year":"2017","journal-title":"Oncotarget"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1158\/1078-0432.CCR-19-3492","article-title":"Pathological complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: A comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1007\/s12032-012-0195-y","article-title":"Increased efficacy of a dose-dense regimen of neoadjuvant chemotherapy in breast carcinoma","volume":"29","author":"Melichar","year":"2012","journal-title":"Med. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","article-title":"Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741","volume":"21","author":"Citron","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_7","first-page":"101162","article-title":"Benefit from dose-dense adjuvant chemotherapy for breast cancer: Subgroup analyses from the randomised phase 3 PANTHER trial","volume":"49","author":"Matikas","year":"2025","journal-title":"Lancet Reg. Health-Eur."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1200\/JCO-24-01875","article-title":"Adjuvant Dose-Dense Chemotherapy in Hormone Receptor\u2013Positive Breast Cancer","volume":"43","author":"Filho","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_9","first-page":"3934","article-title":"Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma","volume":"7","author":"Fornier","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1093\/jnci\/dji398","article-title":"Dose-dense adjuvant chemotherapy in early breast cancer patients: Results from a randomized trial","volume":"97","author":"Venturini","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/bcr1007","article-title":"Dose-dense adjuvant chemotherapy for primary breast cancer","volume":"7","author":"Fornier","year":"2005","journal-title":"Breast Cancer Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/s41416-020-0816-8","article-title":"Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study","volume":"122","author":"Blondeaux","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/S0140-6736(14)62048-1","article-title":"Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: An open-label, 2 \u00d7 2 factorial, randomized phase 3 trial","volume":"385","author":"Mastro","year":"2015","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S1470-2045(22)00632-5","article-title":"Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): End-of-study results from a randomized, phase3 trial","volume":"23","author":"Mastro","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/annonc\/mdg069","article-title":"Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: A randomized phase III trial in locally advanced breast cancer","volume":"14","author":"Baldini","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.clbc.2023.02.009","article-title":"Observation Effectiveness of Dose-Dense Neoadjuvant Anthracycline Sequential Weekly Paclitaxel for Triple-Negative Breast Cancer Patients","volume":"23","author":"Wang","year":"2023","journal-title":"Clin. Breast Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12957-018-1424-4","article-title":"Survival benefit of pure dose-dense chemotherapy in breast cancer: A meta-analysis of randomized controlled trials","volume":"16","author":"Zhou","year":"2018","journal-title":"World J. Surg. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.prp.2017.07.002","article-title":"Prognostic value of IMP3 expression as a determinant of chemosensitivity in triple negative breast cancer","volume":"213","author":"Ohashi","year":"2017","journal-title":"Pathol. Res. Pract."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1272\/jnms.JNMS.2025_92-109","article-title":"Impact of IMP3 Expression on Chemotherapy Response and Prognosis in Triple-Negative Breast Cancer: A Retrospective Cohort Study","volume":"92","author":"Yagi","year":"2025","journal-title":"J. Nippon. Med. Sch."},{"key":"ref_20","unstructured":"Japanese Breast Cancer Society (2022). Breast Cancer Practice Guidelines 2022 (Treatment Edition), Kanehara & Co., Ltd.. (In Japanese)."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S1470-2045(17)30404-7","article-title":"Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK\/05\/19): A multicentre, phase 3, open-label, randomised, controlled trial","volume":"18","author":"Cameron","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_22","first-page":"5519","article-title":"Anemia requiring transfusion in breast cancer patients on dose-dense chemotherapy: Prevalence, risk factors, cost and effect on disease outcome","volume":"30","author":"Sharma","year":"2022","journal-title":"Support. Care Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1272\/jnms.JNMS.2024_91-605","article-title":"Organizing Pneumonia Associated with Pneumocystis jirovecii in a Patient Receiving Dose-Dense Chemotherapy for Breast Cancer: A Case Report","volume":"91","author":"Yagi","year":"2024","journal-title":"J. Nippon. Med. Sch."},{"key":"ref_24","unstructured":"Truong, J., and Ashurst, J.V. (2025). Pneumocystis jirovecii Pneumonia. StatPearls [Internet], StatPearls. Available online: https:\/\/pubmed.ncbi.nlm.nih.gov\/29493992\/."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/cam4.344","article-title":"G-CSF utilization rate and prescribing patterns in United States: Associations between physician and patient factors and GCSF use","volume":"3","author":"Barnes","year":"2014","journal-title":"Cancer Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1200\/jco.2016.34.7_suppl.101","article-title":"Reduction of inappropriate prophylactic pegylated granulocyte colonystimulating factor use for patients with non-small-cell. lung cancer who receive chemotherapy: An ASCO quality training program project of the Cleveland Clinic Taussig Cancer Institute","volume":"12","author":"Goodman","year":"2016","journal-title":"Am. Soc. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","article-title":"Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review","volume":"90","author":"Lyman","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Smith","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JOP.2012.000662","article-title":"Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic","volume":"9","author":"Waters","year":"2012","journal-title":"J. Oncol. Pract."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Mahtani, R., Crawford, J., Flannery, S.M., Lawrence, T., Schenfeld, J., and Gawade, P.L. (2021). Prophylactic pegfilgrastim to prevent febrile neutropenia among patients receiving biweekly (Q2W) chemotherapy regimens: A systematic review of efficacy, effectiveness and safety. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08258-w"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/cpt.2263","article-title":"Nested Case-Control Study Utilizing MID-NET\u00ae on Thrombocytopenia Associated with Pegfilgrastim in Patients Treated with Antineoplastic Agents","volume":"110","author":"Kajiyama","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Yildirim, E.C., Atag, E., Semiz, H.S., Unal, O.U., Uzun, M., Aksoy, S.O., Durak, M.G., and Karaoglu, A. (2015). Achieving treatment goals in older breast cancer patients receiving neoadjuvant chemotherapy. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-93203-1"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10549-008-0116-0","article-title":"Feasibility and toxicity of dose-dense adjuvant chemotherapy in older women with breast cancer","volume":"117","author":"Zauderer","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for Early Triple-Negative Breast Cancer","volume":"382","author":"Peter","year":"2020","journal-title":"N. Engl. J. Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/8\/441\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:24:26Z","timestamp":1760034266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/8\/441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["curroncol32080441"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32080441","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]}}}